10 / 30
Page 81
conferenceseries
.com
Volume 7
Pharmaceutical Regulatory Affairs: Open Access
ISSN: 2167-7689
Pharma Europe 2018
May 07-09, 2018
May 07-09, 2018 | Frankfurt, Germany
15
th
Annual European Pharma Congress
Preliminary studies regarding biocompatibility of encapsulated dopamine in a nanoporous matrix of
TiO
2
as a material for store and release of dopamine
P Vergara-Aragón
1
, G Valverde-Aguilar
2
, M Vázquez-García
1
, B Hernández-Téllez
1
, A L Camacho Álvarez
1
, M J Jiménez Gutiérrez
1
, L C Ibarra
Montenegro
1
, H González Sánchez
1
and
D Santiago López
3
1
National Autonomous University of Mexico, Mexico
2
Instituto Politécnico Nacional, Mexico
3
Universidad Autónoma de la Ciudad de México, Mexico
T
he development of formulations based on titanium dioxide to store dopamine (TiO
2
/DA) minimizes the oxidation of it by
protecting it from direct exposure to natural light and air. It also fulfills a second function that is the release of dopamine
(DA) for long periods in a rat model of hemiparkinsonism. A critical point is the toxicity of these materials that has led
us to perform biocompatibility tests on these TiO
2
/DA implants. The first biocompatibility studies on TiO
2
/DA implant are
presented here. Presterilized samples of the matrix were implanted subcutaneously and intraperitoneally in male Wistar rats.
Scanning electron microscopy and histological examination of implanted samples and surrounding tissues were performed;
subcutaneous implant was 0.095 g/DA per 20 ml of TiO
2
. Histological examination of implanted samples and surrounding
tissues revealed no evidence of acute or chronic foreign body inflammatory response. The fibrous capsules surrounding the
implant remained thin (<100 μm) after more than threemonths in situ, while the surrounding tissue remainedwell vascularized;
intraperitoneal implant was 0.02 ml/DA per 20 ml of TiO
2
. The histological analysis for the liver, heart, lung, kidney, spleen,
muscles and brain did not show structural macroscopic changes. It did not show an inflammatory response either (TNF-a, IL-
6
and cellular infiltration), between the control group and the experimental groups. Also, the implants lingered encapsulated on
tissue after three months; intraperitoneal implant was 0.13 g/DA per 20 ml of TiO
2
. It was observed that a mild inflammatory
effect and the presence of mononucleocytes within the group which received the highest dose of TiO
2
/DA. The results of this
analysis suggest that there is no contamination across the organs due to the implants. It is possible to suggest the compatibility
of the TiO
2
/DA implant with the rat tissue, and thus, justify a further investigation about its potential use as biomaterial for
storing and releasing drugs.
Recent Publications
1.
P Vergara-Aragón (2017) Is it possible to reverse the motor alterations with dopamine supply content in an amorphuous
matrix in a hemiparkinsonian rat model? Phamaceutical Reg Affairs 6(1):53.
2.
S Hernández Castro and P Vergara Aragón (2017) A PET study with [11-C] raclopride in hermiparkinsonism model:
preliminary results on the effect of a TiO
2
DAmatrix implanted in the caudate nucleus. Phamaceutical Reg Affairs 6(1):52.
3.
Blanca Meza Aupart and Vergara Aragón P (2017) Evaluation of the effects that produce a micro-implant with dopamine
stabilized and inserted in the caudate nucleus in hemiparkinsonism rat model induced on motor activity and its
relationship to the levels of dopamine. Phamaceutical Reg Affairs 6(1):54.
4.
Velázquez-Paniagua M, Ana María Vázquez-Álvarez, María Guadalupe Valverde-Aguilar y and Patricia Vergara-Aragón
(2016) Current treatments in Parkinson’s including the proposal of an innovative dopamine micro implant. Revista del
Hospital General de México. Rev Med Hosp Gen Mex. 79(2):79–87.
5.
Valverde-Aguilar G, Prado-Prone G, Vergara-Aragón P, García-Macedo J, Santiago P, et al. (2014) Photoconductivity
studies on nanoporous TiO
2
/dopamine films prepared by sol–gel method. Applied Physics A 116(3):1075–1084.
Biography
P Vergara-Aragón is an MD and PhD in Psychological Research and has worked in the Faculty of Medicine, UNAM in Mexico for more than 30 years. She
collaborates with the Physics Institute of the National Polytechnique Institute. Her research is focused in the field of Parkinson’s disease (PD), study of the
nigrostriatal pathway degeneration, and involved mechanism caused by rotenone and 6-OHDA; stabilization of dopamine and its use as treatment for PD; the
study of the effects produced
in vivo
of a TiO
2
amorphous matrix as a reservoir for dopamine in a PD model in rats; description of the cognitive implications of PD
in patients; toxicity and biological implications of rotenone exposure in animal models.
paty_
ver@hotmail.comP Vergara-Aragón et al., Pharmaceut Reg Affairs 2018, Volume 7
DOI: 10.4172/2167-7689-C1-031